NCT00168012View on ClinicalTrials.gov

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

September 30, 2005

Conditions
AgammaglobulinemiaIgG DeficiencyCommon Variable Immunodeficiency
Interventions
DRUG

Immunoglobulins Intravenous (Human)

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY